226 related articles for article (PubMed ID: 31883617)
1. The influence of long non-coding RNAs on the response to chemotherapy in ovarian cancer.
Wambecke A; Ahmad M; Lambert B; Joly F; Poulain L; Denoyelle C; Meryet-Figuiere M
Gynecol Oncol; 2020 Mar; 156(3):726-733. PubMed ID: 31883617
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic Pathways Offer Targets for Ovarian Cancer Treatment.
Gyparaki MT; Papavassiliou AG
Clin Breast Cancer; 2018 Jun; 18(3):189-191. PubMed ID: 29042129
[No Abstract] [Full Text] [Related]
3. Targeting DNA Damage Response and Repair as a Therapeutic Strategy for Ovarian Cancer.
Konstantinopoulos PA; Matulonis UA
Hematol Oncol Clin North Am; 2018 Dec; 32(6):997-1010. PubMed ID: 30390770
[TBL] [Abstract][Full Text] [Related]
4. Downregulation of miR-503 contributes to the development of drug resistance in ovarian cancer by targeting PI3K p85.
Wu D; Lu P; Mi X; Miao J
Arch Gynecol Obstet; 2018 Mar; 297(3):699-707. PubMed ID: 29327155
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of Drug Resistance in High-Grade Serous Ovarian Cancer.
Freimund AE; Beach JA; Christie EL; Bowtell DDL
Hematol Oncol Clin North Am; 2018 Dec; 32(6):983-996. PubMed ID: 30390769
[TBL] [Abstract][Full Text] [Related]
6. Recent advancements in therapeutic targeting of the Warburg effect in refractory ovarian cancer: A promise towards disease remission.
Tyagi K; Mandal S; Roy A
Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188563. PubMed ID: 33971276
[TBL] [Abstract][Full Text] [Related]
7. Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status.
Gadducci A; Guarneri V; Peccatori FA; Ronzino G; Scandurra G; Zamagni C; Zola P; Salutari V
J Ovarian Res; 2019 Jan; 12(1):9. PubMed ID: 30691488
[TBL] [Abstract][Full Text] [Related]
8. miR-146b promotes cell proliferation and increases chemosensitivity, but attenuates cell migration and invasion via FBXL10 in ovarian cancer.
Yan M; Yang X; Shen R; Wu C; Wang H; Ye Q; Yang P; Zhang L; Chen M; Wan B; Zhang Q; Xia S; Lu X; Shao G; Zhou X; Yu J; Shao Q
Cell Death Dis; 2018 Nov; 9(11):1123. PubMed ID: 30409964
[TBL] [Abstract][Full Text] [Related]
9. Olaparib for the treatment of relapsed ovarian cancer with a BRCA1/2 mutation.
Stewart J; George A; Banerjee S
Expert Rev Anticancer Ther; 2018 Oct; 18(10):947-958. PubMed ID: 30092674
[TBL] [Abstract][Full Text] [Related]
10. Mirvetuximab Soravtansine Combination Yields Encouraging Response Rates in Ovarian Cancer.
Fowler M
Oncology (Williston Park); 2020 Jul; 34(7):250. PubMed ID: 32674207
[TBL] [Abstract][Full Text] [Related]
11. Ivermectin Augments the In Vitro and In Vivo Efficacy of Cisplatin in Epithelial Ovarian Cancer by Suppressing Akt/mTOR Signaling.
Zhang X; Qin T; Zhu Z; Hong F; Xu Y; Zhang X; Xu X; Ma A
Am J Med Sci; 2020 Feb; 359(2):123-129. PubMed ID: 32039764
[TBL] [Abstract][Full Text] [Related]
12. Advances in the treatment of platinum resistant epithelial ovarian cancer: an update on standard and experimental therapies.
Leung SOA; Konstantinopoulos PA
Expert Opin Investig Drugs; 2021 Jul; 30(7):695-707. PubMed ID: 34082614
[No Abstract] [Full Text] [Related]
13. Induction of autophagic cell death in human ovarian carcinoma cells by Antrodia salmonea through increased reactive oxygen species generation.
Yang HL; Lin RW; Karuppaiya P; Mathew DC; Way TD; Lin HC; Lee CC; Hseu YC
J Cell Physiol; 2019 Jul; 234(7):10747-10760. PubMed ID: 30584666
[TBL] [Abstract][Full Text] [Related]
14. A Proof of Concept for Biomarker-Guided Targeted Therapy against Ovarian Cancer Based on Patient-Derived Tumor Xenografts.
Palmer AC; Plana D; Gao H; Korn JM; Yang G; Green J; Zhang X; Velazquez R; McLaughlin ME; Ruddy DA; Kowal C; Muszynski J; Bullock C; Rivera S; Rakiec DP; Elliott G; Fordjour P; Meyer R; Loo A; Kurth E; Engelman JA; Bitter H; Sellers WR; Williams JA; Sorger PK
Cancer Res; 2020 Oct; 80(19):4278-4287. PubMed ID: 32747364
[TBL] [Abstract][Full Text] [Related]
15. Molecular mechanisms of drug resistance in ovarian cancer.
Norouzi-Barough L; Sarookhani MR; Sharifi M; Moghbelinejad S; Jangjoo S; Salehi R
J Cell Physiol; 2018 Jun; 233(6):4546-4562. PubMed ID: 29152737
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-128/homeobox B8 axis regulates ovarian cancer cell progression.
Li R; Gong L; Li P; Wang J; Bi L
Basic Clin Pharmacol Toxicol; 2019 Dec; 125(6):499-507. PubMed ID: 31271703
[TBL] [Abstract][Full Text] [Related]
17. miR-211 facilitates platinum chemosensitivity by blocking the DNA damage response (DDR) in ovarian cancer.
Wang T; Hao D; Yang S; Ma J; Yang W; Zhu Y; Weng M; An X; Wang X; Li Y; Wu D; Tang J; Yang C; He Y; Zhang L; Jin X; Wang G; Li Z; Zheng T; Meng H; Feng Y; Li X
Cell Death Dis; 2019 Jun; 10(7):495. PubMed ID: 31235732
[TBL] [Abstract][Full Text] [Related]
18. Predictive biomarkers of platinum and taxane resistance using the transcriptomic data of 1816 ovarian cancer patients.
Fekete JT; Ősz Á; Pete I; Nagy GR; Vereczkey I; Győrffy B
Gynecol Oncol; 2020 Mar; 156(3):654-661. PubMed ID: 31973910
[TBL] [Abstract][Full Text] [Related]
19.
Jeleniewicz W; Cybulski M; Nowakowski A; Stenzel-Bembenek A; Guz M; Marzec-Kotarska B; Kotarski J; Stepulak A
Anticancer Res; 2019 Apr; 39(4):1821-1827. PubMed ID: 30952722
[TBL] [Abstract][Full Text] [Related]
20. Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial.
Konstantinopoulos PA; Barry WT; Birrer M; Westin SN; Cadoo KA; Shapiro GI; Mayer EL; O'Cearbhaill RE; Coleman RL; Kochupurakkal B; Whalen C; Curtis J; Farooq S; Luo W; Eismann J; Buss MK; Aghajanian C; Mills GB; Palakurthi S; Kirschmeier P; Liu J; Cantley LC; Kaufmann SH; Swisher EM; D'Andrea AD; Winer E; Wulf GM; Matulonis UA
Lancet Oncol; 2019 Apr; 20(4):570-580. PubMed ID: 30880072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]